Department updates

» Go to news main

Dr. Ross contributes to CMAJ story on possible medical isotope shortage

Posted by Carolyn Brown, CMAJ on January 20, 2016 in Nuclear Medicine
Dr. Andrew Ross
Dr. Andrew Ross

The Chalk River, Ontario, reactor once produced about 40% of the global supply of molybdenum-99, which is purified for use in myocardial perfusion imaging, bone and renal scans and other imaging.

From Canadian Medical Association Journal

Will there be a medical isotope shortage when the National Research Universal (NRU) reactor in Chalk River, Ontario, stops production in October?

It's a multimillion dollar question. The last shortage in 2009, due to an NRU outage, cost an estimated $5 million in Ontario alone due to the increase in the price of isotopes.

While the federal government says that a "significant, prolonged disruption in the global supply that would affect patients" is "unlikely," the Organisation for Economic Cooperation and Development (OECD) and Canadian physicians are warning of a possible shortfall before new sources reach commercial production. To cover serious shortages, the NRU will be in "hot standby mode" until March 2018, CMAJ has learned.

It's a situation that has Dr. Andrew Ross worried. A nuclear medicine physician at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia, Ross is the president of the Canadian Association of Nuclear Medicine. "One of my biggest concerns is the lack of transparency in what is going on, particularly vis-à-vis our Canadian situation," he said.

Ross asked the previous federal government to establish a committee to ensure a stable isotope supply. "One of the problems with the supply chain is that there is a three- to seven-day window before things become much worse very quickly. You cannot stockpile radioactivity. Uranium has a long half-life, but the moly [molybdenum isotope made from uranium] half-life is three days."

Previous outages of the NRU and other reactors supplying large proportions of the world's isotopes highlighted how fragile the supply chain is, he said.

Supply currently relies on a few aging reactors around the world. At 58 years in service, the NRU is the oldest active nuclear reactor. At one time, it produced around 40%-50% of the global supply of molybdenum-99, which accounts for about 80% of medical isotope requirements. Molybdenum-99 is purified to produce technetium-99m, used mainly in myocardial perfusion imaging, but also in bone and renal scans and other imaging.

In an email to CMAJ, Micheline Joanisse, a spokesperson for Natural Resources Minister James Carr, stated that the NRU's production has fallen to about 10%- 15% of the world supply of molybdenum-99. The NRU also produces other specialized isotopes, including an estimated 85% of the world supply of medical-grade cobalt-60 for cancer radiotherapy.

Joanisse explained why the government decided to stop NRU isotope production and eventually decommission the reactor. The federal government has always subsidized the NRU, which is also used for scientific research, but maintenance and operating costs have increased as the reactor aged. Returning it to service after a heavy-water leak due to corrosion of a reactor vessel in 2009 cost the federal government $114 million, and operations since 2008 have cost $351 million. As well, the reactor uses highly enriched uranium, which is being phased out around the world under nuclear nonproliferation agreements, as it has potential for misuse in weapons.

Another major world isotope reactor, OSIRIS in France, will go offline this year, according to a report by the OECD's Nuclear Energy Agency (NEA). After that, the NEA states, there may be problems meeting world demand in case of "adverse events" such as outages at major suppliers. A lot depends on when new sources in Canada and around the world become operational.

There is a window in 2017 and early 2018, before other sources are up and running, when supply will be tight, states the NEA report. The NEA is relying on the NRU being available in a "hot standby mode" during this window in case of shortfalls, as "a useful stopgap."

Joanisse clarified that "hot standby" means that "production of molybdenum-99 could be resumed sufficiently rapidly to address a significant, prolonged shortage … that would impact patients." But the government plans to restart production only if there is such a shortage.

"This is a worldwide problem. It's a very, very integrated system. When things go south, it will affect everybody," said Ross. "My biggest hope is that, over the course of the next six months, we can get the new federal government to understand this. If there is a system by which we understand that NRU will be able to start up again, the danger of supply problems will be majorly mitigated."


All comments require a name and email address. You may also choose to log-in using your preferred social network or register with Disqus, the software we use for our commenting system. Join the conversation, but keep it clean, stay on the topic and be brief. Read comments policy.

comments powered by Disqus